Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

. At January 31, 2008, the company had $20,063,000 in cash and cash equivalents compared to $16,044,000 at fiscal year end April 30, 2007.

"The past quarter was highlighted by a major milestone in our oncology program, as we dosed the first patients in a Phase II trial evaluating bavituximab in combination with chemotherapy in patients with breast cancer," said Steven W. King, president and CEO of Peregrine. "We also received regulatory approval to initiate two additional bavituximab Phase II cancer trials -- a second breast cancer study and a trial in patients with non-small cell lung cancer, a leading cause of cancer deaths worldwide. Planning for these trials is well underway and we anticipate initiating both studies next month. We also made progress in our Cotara clinical program in patients with glioblastoma multiforme (GBM), today announcing promising data from the ongoing dosimetry and Phase II trials showing that several patients are already surviving longer than the expected six-month median survival time for this patient population, with the longest surviving patient now at 15 months post-treatment. Patients who are continuing in the trials are being monitored for safety and overall survival, and we look forward to providing further updates on these trials going forward. We have also recently expanded the number of clinical sites in the Phase Il study to eight and also added a distinguished brain cancer center and experienced Cotara clinical study site -- the Barrow Neurological Institute -- to our dosimetry study in the U.S."

Mr. King added, "Our initiative to raise awareness for the bavituximab and Cotara programs in the scientific and medical communities scored gains, including an oral presentation covering the clinical experience to date in the bavituximab Phase I cancer program at Angio 2008, an oral presentation of clinical data from our Phase I bavituximab trial in hepatitis C patients at the prestigious 2007 Liver Meeting(R), a recent
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... the Best in the Nation ,, PHILADELPHIA, ... announces it has been granted Magnet(R) recognition by ... Program(R). Magnet(R) is one of the highest levels ... achieve, and places Hahnemann among the five percent ... this prestigious distinction. ,, At 9:00 am on ...
(Date:12/16/2009)... /PRNewswire/ -- Capitalizing on the ... and an active venture capital market, leaders from ... Retirement Fund, Indiana University, Purdue University, the University ... Credit Suisse today announced the establishment of the ... of funds. ,, Organized through BioCrossroads, Indiana,s initiative ...
(Date:12/16/2009)... Sequenom, Inc. (Nasdaq: SQNM ), today announced ... David Pendarvis to its board of directors. ... F. Buechler, Ph.D., was president, chief scientific officer ... 1994, Dr. Buechler was Biosite,s director of chemistry. ... senior research scientist for the diagnostics research and ...
(Date:12/16/2009)... 16 Eppendorf has initiated an,import ... SP systems for,infringement of European patent EP ... the,identification and/or the quantification of a target ... imports of the respective products into any ... required to confiscate any,violating products. , ...
Breaking Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2
... Wisconsin companies that ranked among the best places to ... ranked highly because they offer employee incentives designed to ... Northwestern Mutual Life Insurance Co. , Milwaukee, American ... Inc. , Green Bay, all fell within the top ...
... and disposing of excess nuclear fuel may seem like ... in Janesville has obtained the rights to a technology ... NorthStar Nuclear Medicine, Inc. , an early-stage developer of ... treatment by processing small amounts of unused nuclear fuel ...
... proponent of alternative energy, has joined the biodiesel producer ... ,"We are very pleased to have a partner with Mark's ... Hartmann, company CEO. "He is a perfect fit for Great ... fuel technology." , ,Daugherty spent the past several years as ...
Other Biology Technology:Wisconsin companies among Best IT Workplaces 2NorthStar finds cancer-fighting use for nuclear fuel 2
(Date:12/16/2009)... Bank is a vital source of financial and technical ... glance, this may not appear to be connected to ... of Earth,s environment are intrinsically linked. , Global climate ... poverty and advancing development in the poorest countries and ... , These factors have led to a growing demand ...
(Date:12/16/2009)... exposure to pesticides in rivers and basins may ... populations. In addition to the widespread deterioration of ... commonly used pesticides may further inhibit the recovery ... efforts are currently underway to restore Pacific salmon ... says David Baldwin of the National Oceanic and ...
(Date:12/16/2009)... researcher will lead the coordinating center for a consortium ... of stem cell research. Michael L. Terrin, M.D.,C.M.,M.P.H., professor ... National Heart, Lung and Blood Institute (NHLBI) to coordinate ... will be called the NHLBI Progenitor Cell Biology Consortium. ... million grant over seven years. , ...
Breaking Biology News(10 mins):ESA and World Bank move toward closer collaboration 2ESA and World Bank move toward closer collaboration 3ESA and World Bank move toward closer collaboration 4Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3Fighting disease outbreaks with 2 way health information exchange 57774 1Fighting disease outbreaks with 2 way health information exchange 57774 2Rosetta Stone of supervolcanoes discovered in Italian Alps 9998 1Rosetta Stone of supervolcanoes discovered in Italian Alps 9998 2Rosetta Stone of supervolcanoes discovered in Italian Alps 9998 31 million euro EU grant for MDC diabetes researcher Dr Francesca M Spagnoli 9994 11 million euro EU grant for MDC diabetes researcher Dr Francesca M Spagnoli 9994 2
... (NHGRI), one of the National Institutes of Health (NIH), ... target 13 more organisms as part of its ongoing ... knowledge and improve human health. , The National Advisory ... federally chartered committee that advises NHGRI on program priorities ...
... known to lack an antibody-mediated immune response, and ... they produce protective proteins in response to bacterial ... effectors produced at a first infection still function ... raise important issues in insect research which will ...
... the gold standard for treating newborns suffering from opiate ... superior to sedatives for treating infants born to women ... appear to better "ameliorate the withdrawal, facilitate feeding and ... new systematic reviews done by David Osborn, a neonatologist ...
Other Biology News:NHGRI Selects 13 More Organisms for Genome Sequencing 2NHGRI Selects 13 More Organisms for Genome Sequencing 3NHGRI Selects 13 More Organisms for Genome Sequencing 4NHGRI Selects 13 More Organisms for Genome Sequencing 5The very defensive caterpillar 2Opiates Better Than Sedatives For Treating Newborns In Withdrawal 2
... Guava has made microcapillary flow cytometry accessible ... experts alike will appreciate the latest addition ... Pluseasy to use, surprising affordable, and very ... system includes such features as absolute cell ...
...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Fingerprinting II dimensioning techniques is an optional module that adds principal component analysis, multidimensional scaling, discriminant analysis and MANOVA, and self-organizing maps to the Fin...
Biology Products: